How much does a box of Quizartinib cost?

Quizartinib is an oral, highly effective type II inhibitor of FLT3. This drug is specifically indicated for the treatment of adult patients with acute myeloid leukemia (AML) who are positive for the FLT3-ITD (internal tandem repeat) mutation. FLT3-ITD mutations are common in AML patients, and their activation can lead to abnormal proliferation and survival signaling, thereby promoting the development of AML. Quizartinib inhibits FLT3kinase activity and prevents receptor autophosphorylation, thereby inhibiting downstream FLT3 receptor signaling, blocking FLT3-ITD-dependent cell proliferation, thereby inhibiting the growth and proliferation of leukemia cells.

In clinical studies, quizartinib has performed well, with significant efficacy and high safety. It can be used alone or in combination with standard cytarabine and anthracyclines as induction and consolidation therapy in newly diagnosed patients with FLT3-ITD-positive AML, as well as maintenance monotherapy after consolidation chemotherapy. In addition, quizartinib has also been proven to have a very high efficacy in patients with certain types of leukemia, and can significantly extend the progression-free survival of patients and even enable some patients to achieve complete remission.

However, the use of quizartinib is also associated with certain side effects and risks. Common side effects include nausea, vomiting, diarrhea, fatigue, headache and other gastrointestinal and nervous system discomforts. In addition, quizartinib may also prolong the QT interval and increase the risk of arrhythmia, so close monitoring of electrocardiogram and heart rate is required during use. Quizartinib is contraindicated in patients with severe hypokalemia, severe hypomagnesemia, long QT syndrome, or a history of ventricular arrhythmias or torsade de pointes.

Quizatinib is not yet available in China, so domestic patients cannot purchase it directly. However, the drug has sales records overseas. The original version (17.7mg, 28 tablets) launched in Europe is expensive, close to 80,000 yuan; while the generic version in Laos is affordable, about 1,800 yuan (17.7mg, 14 tablets).

Quizartinib is available only from certified pharmacies under a special program in which patients must be registered and understand the risks and benefits of quizartinib. Despite some side effects, quizartinib, as a targeted drug, provides a new treatment option for patients with acute myeloid leukemia, especially showing good results in the treatment of relapsed or refractory AML.

xa0

Reference: https://www.drugs.com/mtm/quizartinib.html